Finance

Lists
BVNRY:OTCMKTS
Bavarian Nordic A/S - ADR
USD 9,20
0,00%
(0,00) 1D
21 Jul., 12:41:51 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BVNRY...
Mkt. cap
2,15 mjd
Avg. vol.
2,95 k
Volume
191,00
P/E ratio
12,71
52-wk high
USD 13,00
52-wk low
USD 8,67
EPS
USD 0,72
Beta
1,39
Shares outstanding
237,73 m
No. of employees
2 k
Mkt. cap
2,15 mjd
Avg. vol.
2,95 k
Volume
191,00
P/E ratio
12,71
52-wk high
USD 13,00
52-wk low
USD 8,67
EPS
USD 0,72
Beta
1,39
Shares outstanding
237,73 m
No. of employees
2 k
News stories
From sources across the web
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development. In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination. Wikipedia
About Bavarian Nordic A/S - ADR
CEOPaul Chaplin
Employees1,86 k
Founded01 Jul. 1992
Headquarters-
Sector-
Websitebavarian-nordic.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
1,65 mjd
1,79 mjd
1,45 mjd
1,06 mjd
Cost of goods sold
737,88 m
901,84 m
866,52 m
583,64 m
Cost of revenue
737,88 m
901,84 m
866,52 m
583,64 m
Research and development expenses
293,26 m
133,20 m
181,74 m
175,14 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
249,40 m
415,41 m
352,14 m
306,07 m
Operating expense
542,66 m
548,52 m
533,88 m
481,21 m
Total operating expenses
1,28 mjd
1,45 mjd
1,40 mjd
1,06 mjd
Operating income
370,96 m
344,56 m
50,55 m
-7,01 m
Other non operating income
-9,01 m
-1,75 m
-1,74 m
-1,71 m
EBT including unusual items
373,35 m
1,17 mjd
28,19 m
23,32 m
EBT excluding unusual items
372,26 m
361,71 m
62,45 m
23,72 m
Income tax expense
10,78 m
77,02 m
326,99 m
6,36 m
Effective tax rate
2,89%
6,58%
1 159,86%
27,30%
Other operating expenses
-
-88,00 k
-
-
Net income
362,57 m
1,09 mjd
-298,80 m
16,95 m
Net profit margin
21,95%
60,89%
-20,59%
1,60%
Earnings per share
-
-
-3,30
-
Interest and investment income
7,42 m
12,90 m
19,84 m
14,86 m
Interest expense
-1,57 m
-1,37 m
-2,18 m
-1,41 m
Net interest expenses
5,84 m
11,53 m
17,66 m
13,45 m
Depreciation and amortization charges
-
-
-
-
EBITDA
541,78 m
515,50 m
166,77 m
165,45 m
Gain or loss from assets sale
-
-
18,43 m
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer